Enterprise Value
715.2M
Cash
435.7M
Avg Qtr Burn
-41.66M
Short % of Float
14.19%
Insider Ownership
0.14%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) + Sunitinib Details Cancer, Gastrointestinal stromal tumors | Phase 3 Data readout | |
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) Details Nonadvanced systemic mastocytosis | Phase 2 Data readout | |
Bezuclastinib (CGT9486) (KIT exon 17 inhibitor) Details Systemic Mastocytosis | Phase 2 Data readout | |
CNS-penetrant ErbB2 program Details Solid tumor/s | IND Submission |